Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2026-03-20 @ 6:17 AM
Study NCT ID:
NCT02109666
Status:
COMPLETED
Last Update Posted:
2017-04-19
First Post:
2014-04-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long Term Experience With Abatacept in Routine Clinical Practice
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
Long Term Experience With Abatacept in Routine Clinical Practice
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACTION
Brief Summary:
The purpose of this study is to estimate the retention rate of Abatacept over 24 months in routine clinical practice in every participating country depending on the treatment line.
Detailed Description:
Time Perspective: Other: Collection of the baseline data collected at Abatacept IV initiation, prospectively or retrospectively within maximum 3 months following the first administration. Other assessments are collected during the follow up period (maximum of 2 years by patient)
Biospecimen Retention: None Retained excepted for a local sub study (in Spain) where sample with DNA was retained
Biospecimen Retention: None Retained excepted for a local sub study (in Spain) where sample with DNA was retained
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: